Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellen...
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing...
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit...
Combined platform connects 250,000+ patients, 40,000+ clinicians, and 90+ biopharma partners—creating a real-world network for precision medi...
Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, announced th...
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the p...
Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Pre...
Lonza announced the addition of Redberry SAS to its family, strengthening its position as a global leader in quality control solutions for th...
Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-...
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including C...
BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, announced the successful acquisition of Bi...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and ful...
© 2026 Biopharma Boardroom. All Rights Reserved.
